An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Saety of Ixazomib (NINLARO®) In Combination with lenalodimide and Dexamethasone (IRD) in Patients with multiple Myeloma Previously Receiving a Bortozomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

Sponsor
Takeda (Millennium Pharmaceuticals)

Protocol Number
MM-6

To Learn More Call
201-510-0910